Esperion Therapeutics, Inc.ESPRNASDAQ
Loading
Cash Generation ExpandingExpanding
Percentile Rank86
Studio
Year-over-Year Change

Cash generated from core business operations

Latest
$-13.09M
↑ 88% vs avg
Percentile
P86
Within normal range
Streak
4 yr
Consecutive growthExpanding
Average
$-109.41M
Historical baseline
PeriodValueYoY Change
2025$-13.09M+44.6%
2024$-23.65M+82.5%
2023$-135.49M+22.5%
2022$-174.83M+33.7%
2021$-263.81M-209.7%
2020$-85.18M-21.1%
2019$-70.34M+52.7%
2018$-148.64M-13.2%
2017$-131.30M-175.1%
2016$-47.73M-